Multiple Sclerosis Update
|
|
- Amos Thompson
- 5 years ago
- Views:
Transcription
1 Multiple Sclerosis Update Amanda Stahnke, PharmD, BCACP University of Missouri-Kansas City School of Pharmacy Kansas City Veterans Affairs Honor Annex Kelsey Morris, PharmD University of Kansas Health-System Disclosure and Conflict of Interest Pharmacist and Technician Objectives Amanda Stahnke and Kelsey Morris declare no conflicts of interest, real or apparent, and no financial interests in any company, product, or service mentioned in this program, including grants, employment, gifts, stock holdings and honoraria. At the conclusion of this program, the pharmacist and technician will be able to: 1. Discuss the basic etiology, pathophysiology, and diagnosis of multiple sclerosis (MS) 2. Discuss recently approved disease modifying therapies (DMTs) 3. Identify potential candidates for newly approved DMTs 1
2 Pre-Test Questions 1. The Criteria is utilized in practice to determine the diagnosis of MS. a) Summer b) McDonald c) Sclerosis d) Farmer Pre-Test Questions 2. Which of the following therapies is contraindicated in pregnancy and requires completion of an elimination protocol if pregnancy occurs? a) Ocrelizumab b) Fingolimod c) Dimethyl fumarate d) Teriflunomide Pre-Test Questions 3. Which of the following disease modifying therapies (DMTs) carries a Black Box Warning for progressive multifocal leukoencephalopathy (PML)? Background a) Natalizumab b) Teriflunomide c) Glatiramer acetate d) Peginterferon 2
3 Etiology/Risk factors Pathophysiology Environmental Epstein-Barr Virus (EBV) Cytomegalovirus (CMV) Negative risk factor Geography Vitamin D deficiency Genetics Smoking REFERENCES: Pharmacotherapy, 9 th Ed. 2014; Porth s Pathophysiology, 9 th Ed. 2014; REFERENCES: J Rehabil Res Dev 2006;43(1): Pathophysiology Pathophysiology T-cells: Expression of alpha-4 integrin (adhesion molecule) Cytokine and nitric oxide production Matrix metalloproteinase production B-cells: Antigen presentation Autoantibody production Cytokine regulation Formation of ectopic lymphoid aggregates in the meninges REFERENCES: Pharmacotherapy, 9 th Ed. 2014; Rehabil Res Dev 2006;43(1): Neurodegener Dis Manag. 2016;6(1): N Engl J Med, 2017;376: REFERENCES: Nat Rev Clin Oncol. 2014;11: Nature Clinical Practice Neurology. 2008;4:
4 Diagnosis Diagnosis History Birthplace, Family history (FHx), Travel, Past medical history (PMH), Signs and symptoms- acute exacerbation Laboratory tests Neurological Exam Cognitive Exam MRI = magnetic resonance imaging Lumbar puncture Oligoclonal bands REFERENCES: Diagnosis 2010 McDonald Criteria Acute exacerbation history MRI history Additional data needed 2 exacerbations 2 lesions None 2 exacerbations 1 lesion DIS or wait for additional exacerbation 1 exacerbation 2 lesions DIT or wait for additional exacerbation 1 exacerbation 1 lesion DIS and DIT or wait for additional exacerbation Continuous progression of disease over 1 year 2 of the 3: 1. DIS (non-spinal cord lesions) 2. DIS (2 or more T2 lesions on spinal cord) 3. Oligoclonal bands and/or elevated IgG index present in CSF Classification Phenotypes: Clinically isolated syndrome (CIS) Radiographically isolated syndrome (RIS)* Relapsing remitting MS (RRMS) Secondary progressive MS (SPMS) Primary progressive MS (PPMS) Modifiers: Active or Not active Progressing or Not progressing MRI = magnetic resonance imaging, DIS = dissemination in space (1 or more T2 lesion in 2 of 4 regions of the CNS typical of MS (periventricular, juxtacortical, infratentorial, or spinal cord), DIT = dissemination in time (presence of gadolinium-enhancing and non-enhancing lesions simultaneously or new lesions on a repeat MRI (T2 or gadolinium-enhancing), CSF = cerebrospinal fluid REFERENCES: Ann Neurol. 2011;69(2): RRMS- Active PPMS- Not active, Progressing PPMS or SPMS - Active, Progressing REFERENCES: Neurology. 2014;83:1-9. 4
5 Expanded Disability Status Scale (EDSS) Disease Management 10.0 = Death due to MS = Completely dependent = Confined to bed/chair; self-care with help = Confined to wheelchair = Walking assistance is needed = Increasing limitation in ability to walk = Impairment is relatively severe = Impairment is mild to moderate = Impairment is minimal = No impairment 0 = Normal neurologic exam REFERENCES: Neurology. 1983;33: Acute exacerbation treatment Steroids Methylprednisolone mg/day IV or mg PO for 3-5 days Other therapy- IVIG, plasmaphoresis, ACTH (Acthar ) Disease modifying therapies Mainstay of management Symptom management Depression, fatigue, bowel/bladder dysfunction, gait abnormalities, IVIG = intravenous immunoglobulin, ACTH = Adrenocorticotropic hormone REFERENCES: Lancet. 2015;386: NICE nice.org.uk/guidance/cg186. Disease Management Goals Decrease attack/exacerbation rate Decrease annualized relapse rate (ARR) Slow progression of disease Disability, MRI findings, Cognition Prevent/limit ADRs Effectively manage symptoms Interferons o β-1a o β-1b o All require titration ARR = Annualized Relapse Rate Disease Modifying Therapies (DMTs) Therapy Maintenance Dosing ARR o Avonex 30mcg IM qweek o Rebif 22 or 44mcg subcut three times per week o Peginterferon (Plegridy ) 125mcg subcut q2weeks o Betaseron or Extavia 0.25mg subcut every other day Glatiramer acetate (Copaxone ) 20mg subcut daily [generic available (Glatopa )] 40mg subcut three times weekly 18% 33.2% 36% 34% 29% 34% Mitoxantrone (Novantrone ) 12mg/m 2 IV q3months 66% Natalizumab (Tysabri ) 300mg IV q4weeks 68% Fingolimod (Gilenya ) 0.5mg PO daily 48-54% Teriflunomide (Aubagio ) 7 or 14mg PO daily ~31% Dimethyl fumarate (Tecfidera ) 240mg PO BID, requires titration 44-49% Alemtuzumab (Lemtrada ) 12mg IV for 5 days, repeated in 1 year for 3 days 49-55% Daclizumab (Zinbryta ) Ocrelizumab (Ocrevus ) REFERENCES: Multiple Sclerosis Coalition
6 New Multiple Sclerosis Therapies Daclizumab Daclizumab (Zinbryta ) FDA approved: May 2016 Indication: Relapsing forms of multiple sclerosis SELECT MOA: humanized monoclonal antibody which binds to the CD25 subunit of the high-affinity interleukin-2 (IL-2) receptor Prevents signaling at the high-affinity IL-2 receptor Allows for increased IL-2 availability for signaling at the intermediate-affinity IL-2 receptor REFERENCES: Lancet. 2013;381:
7 SELECT: Treatment Groups and Study Design SELECT: Primary Endpoint daclizumab 150mg group: 54% reduction in ARR daclizumab 300mg group: 50% reduction in ARR REFERENCES: Lancet. 2013;381: REFERENCES: Lancet. 2013;381: SELECT: Secondary Endpoints More patients relapse free at 52 weeks Significantly fewer new Gd+-enhancing lesions at 52 weeks Gd+ = gadolinium REFERENCES: Lancet. 2013;381: SELECT: Adverse Events Placebo (N = 204) Daclizumab HYP 150mg (N = 208) Adverse events of interest Number of patients (%) Daclizumab HYP 300mg (N = 209) Infections 89 (44) 104 (50) 112 (54) Serious infections 0 6 (3) 3 (1) Cutaneous events 27 (13) 38 (18) 45 (22) Serious cutaneous events 0 2 (<1) 3 (<1) Death 0 1 (<1) 0 Incidence of ALT or AST abnormalities Number of patients (%) 1-3 x ULN 64 (31) 54 (26) 62 (30) 3-5 x ULN 6 (3) 7 (3) 6 (3) >5 x ULN 1 (<1) 9 (4) 8 (4) Injection-site reactionm erythema 3 (1) 4 (2) 4 (2) Malignancy 1 (<1) 1 (<1) 2 (<1) REFERENCES: Lancet. 2013;381:
8 DECIDE: Treatment Groups and Study Design DECIDE REFERENCES: N Engl J Med. 2015;373: DECIDE: Primary and Secondary Endpoints DECIDE: Adverse Events 45% reduction in ARR with daclizumab vs. INF beta-1a Daclizumab HYP (N = 919) Interferon Beta- 1a (N = 922) Event Number of patients (%) Infection Nasopharyngitis Upper respiratory tract infection Urinary tract infection Serious infection 595 (65) 226 (25) 149 (16) 96 (10) 40 (4) 523 (57) 197 (21) 124 (13) 98 (11) 15 (2) Cutaneous events 344 (37) 176 (19) REFERENCES: N Engl J Med. 2015;373: REFERENCES: N Engl J Med. 2015;373:
9 DECIDE: Adverse Events Event Daclizumab HYP (N = 919) Interferon Beta 1-a (N = 922) Hepatic laboratory abnormality Number of patients (%) ALT or AST >3 x ULN 96 (10) 80 (9) ALT or AST >5 x ULN 59 (6) 31 (3) Ocrelizumab ALT or AST >3 x ULN and total bilirubin >2x ULN 7 (1) 1 (<1) EMA = European Medicines Agency REFERENCES: N Engl J Med. 2015;373: Ocrelizumab (Ocrevus ) FDA approved: March 2017 Indication: relapsing or primary progressive forms of multiple sclerosis OPERA I & OPERA II MOA: ocrelizumab is a humanized monoclonal antibody that selectively depletes CD20+ B cells CD20 is a cell-surface antigen that is express on Pre-B cells Mature B cells Memory B cells REFERENCES: N Engl J Med. 2017;376:
10 OPERA I & OPERA II: Treatment Groups OPERA I & OPERA II: Primary and Secondary Endpoints Gd+ = gadolinium OPERA I: 46% lower ARR with ocrelizumab vs. INF beta-1a OPERA II: 47% lower ARR with ocrelizumab vs. INF beta-1a Significantly fewer Gd+ enhancing lesions at 96 weeks REFERENCES: N Engl J Med. 2017;376: REFERENCES: N Engl J Med. 2017;376: OPERA I & OPERA II: Adverse Events ORATORIO REFERENCES: N Engl J Med. 2017;376:
11 ORATORIO: Treatment Groups ORATORIO: Primary Endpoint 6.4% fewer patients experienced disease progression at 12 weeks vs. placebo REFERENCES: N Engl J Med. 2017;376: REFERENCES: N Engl J Med. 2017;376: ORATORIO: Secondary Endpoint ORATORIO: Adverse Events Ocrelizumab (N = 486) Placebo (N =239) 6.1% fewer patients experienced disease progression at 24 weeks vs. placebo REFERENCES: N Engl J Med. 2017;376: Event Number of patients (%) >1 infusion-related reaction (mild-severe) 194 (39.9) 61 (25.5) Serious infection 30 (6.2) 14 (5.9) Neoplasms Breast Basal-cell Adenocarcinoma of cervix Anaplastic large-cell lymphoma Endometrial adenocarcinoma Malignancy fibrous histiocytoma Metastatic pancreatic carcinoma 11 (2.3) 4 (0.8) 3 (0.6) 0 1 (0.2) 1 (0.2) 1 (0.2) 1 (0.2) 2 (0.8) 0 1 (0.4) 1 (0.4) Death 4 (0.8) 1 (0.4) REFERENCES: N Engl J Med. 2017;376:
12 Ocrelizumab: Post-Marketing Updates Post Test: Question #1 KS is a 52 year old white female diagnosed with MS 20 years ago. At the time of diagnosis her MRI showed multiple Gd+ enhancing and non-enhancing lesions in the infratentorial and along her spinal cord and her lumbar puncture was (+) for oligoclonal bands. KS continues to experiences relapses at least yearly and her most recent MRI demonstrated new Gd+ enhancing lesions in the juxtacortical and periventricular regions of her brain. She does not experience worsening of disease outside of relapses. 1. How would you classify KS s disease course? a) Secondary-progressive MS- active, not progressing b) Relapsing-remitting MS- active c) Clinically Isolated Syndrome d) Primary-progressive MS- not active, progressing Post Test: Question #2 Post Test: Question #3 KS has now failed the oral option you selected for her previously (totaling 4 failed therapies). Labs were completed to assist in further therapy selection. Na 141 meq/l 2. Based on clinical trial data and recent FDA post-marketing reports, which of the following therapies would you avoid in KS? a) Ocrelizumab b) Daclizumab K Cl CO2 SCr BUN GLU Ca AST ALT Vit D 3.6 meq/l 106 meq/l 24 meq/l 0.74 mg/dl 14 mg/dl 88 mg/dl 9.5 mg/dl 130 U/L 154 U/L 18 ng/ml 3. To date no reports of progressive multifocal leukoencephalopathy (PML) have been reported with either daclizumab or ocrelizumab. a) True b) False 12
13 Take Home Points The exact cause of MS is still unknown, but multiple risk factors have been identified and several new therapies have been developed within the last few years, specifically daclizumab and ocrelizumab. The choice of therapy is based upon many factors, including patient and provider preference, disease course and severity, patient specific factors, and medication adverse effects. Resources & References Bainbridge JL, Miravalle A, Corboy JR. Pharmacotherapy, 9th Ed. 2014; Porth s Pathophysiology, 9th Ed. 2014; Cudrici C, et al. J Rehabil Res Dev 2006;43(1): Gasperi C, Stüve O, Hemmer B. Neurodegener Dis Manag. 2016;6(1): Hauser SL, Bar-Or A, Comi G, et al. N Engl J Med. 2017;376: Choi SW, Reddy P. Nat Rev Clin Oncol. 2014;11: Dalakas MC. Nature Clinical Practice Neurology. 2008;4: Polman CH, Reingold SC, Banwell B, et al. Ann Neurol 2011;69(2): Lublin FD, Reingold SC, Cohen JH, et al. Neurology. 2014;83:1-9. Kurtzke JF. Neurology. 1983;33: Management. LePage E, Veillard D, Laplaud DA, et al. Lancet. 2015;386: NICE nice.org.uk/guidance/cg186. Costello K, Halper J, Kalb R, et al. The use of disease-modifying therapies in multiple sclerosis: principles and current evidence Gold R, Giovannoni G, Selmaj K, et al. Lancet. 2013;381: Kappos L, Wiendl H, Selmaj K, et al. N Engl J Med. 2015;373: Montalban X, Hauser SL, Kappos L, et al. N Engl J Med. 2017;376: Speaker Contact Information Amanda Stahnke, PharmD, BCACP University of Missouri-Kansas City Department of Pharmacy Practice and Administration- Clinical Assistant Professor Kansas City Veterans Affairs Medical Center Honor Annex Patient-Aligned Care Team Pharmacist in Primary Care stahnkea@umkc.edu Kelsey Morris, PharmD University of Kansas Healthcare System Clinical Ambulatory Care Pharmacist: Neurology-Multiple Sclerosis kmorris8@kumc.edu 13
Biologics and Beyond: Treatment of Multiple Sclerosis. Rita Jebrin, PharmD, BCPS
Biologics and Beyond: Treatment of Multiple Sclerosis Rita Jebrin, PharmD, BCPS Disclosure Information Biologics and Beyond: Treatment of Multiple Sclerosis Rita Jebrin, PharmD, BCPS I have no financial
More informationMULTIPLE SCLEROSIS - REVIEW AND UPDATE
MULTIPLE SCLEROSIS - REVIEW AND UPDATE Luka Vlahovic, MD Neuroimmunology/Multiple Sclerosis Creighton University Medical Center MS is primary demyelinating disease of the central nervous system. MS is
More informationAdvances in the Management of Multiple Sclerosis: A closer look at novel therapies. Disclosures
Advances in the Management of Multiple Sclerosis: A closer look at novel therapies Lily Jung Henson, MD, MMM, FAAN Chief of Neurology Piedmont Healthcare, Atlanta, GA National Association of Managed Care
More informationPediatric MS treatments: What do you start with, when do you switch?
Pediatric MS treatments: What do you start with, when do you switch? Tim Lotze, M.D. Associate Professor of Pediatric Neurology Texas Children s Hospital Baylor College of Medicine Disclosures Clinical
More informationMitzi Joi Williams, MD Neurologist MS Center of Atlanta Atlanta, GA
Mitzi Joi Williams, MD Neurologist MS Center of Atlanta Atlanta, GA Disclosures Consultant and Speaker Bureau member for Biogen-Idec, Pfizer, TEVA Neuroscience, Bayer, EMD Serrono, Questcor, Novartis,
More informationMedication Policy Manual. Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012
Medication Policy Manual Policy No: dru283 Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012 Committee Approval Date: December 16, 2016 Next Review Date: December 2017 Effective Date: January
More informationMedication Policy Manual. Topic: Tecfidera, dimethyl fumarate Date of Origin: May 16, 2013
Medication Policy Manual Policy No: dru299 Topic: Tecfidera, dimethyl fumarate Date of Origin: May 16, 2013 Committee Approval Date: December 16, 2016 Next Review Date: December 2017 Effective Date: January
More informationOcrevus (ocrelizumab)
Ocrevus (ocrelizumab) Policy Number: 5.01.629 Last Review: 04/2018 Origination: 05/2017 Next Review: 04/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Ocrevus
More informationCommittee Approval Date: December 12, 2014 Next Review Date: December 2015
Medication Policy Manual Policy No: dru283 Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012 Committee Approval Date: December 12, 2014 Next Review Date: December 2015 Effective Date: January
More informationClass Update with New Drug Evaluation: Disease-Modifying Drugs for Multiple Sclerosis
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More information1996 vs 2013 MS Phenotype Descriptions of Progressive Disease
Learning Objectives Upon completion, participants should be able to: Describe methods of distinguishing among RRMS, SPMS, and PPMS Incorporate available evidence about emerging and recently approved novel
More informationClinical Policy: Mitoxantrone (Novantrone) Reference Number: CP.CPA.334 Effective Date: Last Review Date: Line of Business: Commercial
Clinical Policy: (Novantrone) Reference Number: CP.CPA.334 Effective Date: 06.01.18 Last Review Date: 05.18 Line of Business: Commercial Coding Implications Revision Log See Important Reminder at the end
More informationMedical Policy An Independent Licensee of the Blue Cross and Blue Shield Association
Ampyra (dalfampridine) Page 1 of 9 Medical Policy An Independent Licensee of the Blue Cross and Blue Shield Association Title: Ampyra (dalfampridine) Prime Therapeutics will review Prior Authorization
More informationPage 1. Multiple Sclerosis. I have no conflicts of interest. Team Menstrual Cycles Waves to Wine for MS. Overview.
Multiple Sclerosis New Developments Jeffrey A. Tice, MD Professor of Medicine Division of General Internal Medicine University of California, San Francisco I have no conflicts of interest Team Menstrual
More informationAnisha Keshavan. Roland Henry, PhD. Proportion of Patients (%) Rituximab 2000mg (n=66) Placebo (n=35)
Two Faces of Multiple Sclerosis February 8, 217 5 T H A N N U A L R E C E N T A D V A N C E S I N N E U R O L O G Y B CELL THERAPY FOR MULTIPLE SCLEROSIS: A NEW DAY? Inflammation Relapsing MS Anisha Keshavan
More informationClinical Policy: Mitoxantrone (Novantrone) Reference Number: CP.PHAR.258 Effective Date: Last Review Date: Line of Business: Medicaid
Clinical Policy: (Novantrone) Reference Number: CP.PHAR.258 Effective Date: 08.01.16 Last Review Date: 05.18 Line of Business: Medicaid Coding Implications Revision Log See Important Reminder at the end
More informationLe Hua, MD. Disclosures Teaching and Speaking: Teva Neurosciences, Genzyme, Novartis Advisory Board: Genzyme, EMD Serono
Le Hua, MD Le Hua, MD, is a staff neurologist at Cleveland Clinic Lou Ruvo Center for Brain Health in Las Vegas, NV. She is involved in clinical trials assessing new therapies for the treatment of MS and
More informationClinical Policy: Natalizumab (Tysabri) Reference Number: ERX.SPA.162 Effective Date:
Clinical Policy: (Tysabri) Reference Number: ERX.SPA.162 Effective Date: 10.01.16 Last Review Date: 05.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationAPPENDIX D SASKATCHEWAN MS DRUGS PROGRAM
APPENDIX D SASKATCHEWAN MS DRUGS PROGRAM PROCEDURE FOR OBTAINING COVERAGE OF MS DRUGS UNDER THE DRUG PLAN Requests are initiated by a physician. The patient and physician complete the application form
More information2. Has this plan authorized this medication in the past for this member (i.e., previous authorization is on file under this plan)?
Pharmacy Prior Authorization AETA BETTER HEALTH KETUCK Multiple Sclerosis Agents (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information,
More information2. Has this plan authorized this medication in the past for this member (i.e., previous authorization is on file under this plan)?
Pharmacy Prior Authorization MERC CARE (MEDICAID) Multiple Sclerosis (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign and
More informationPATIENT INFORMATION: Patient Surname First Name Middle Initial Sex Date of Birth Alberta Personal Health Number M / F Year Month Day
Applicant must be covered on an Alberta Government sponsored drug program. Page 1 of 6 PATIENT INFORMATION: Patient Surname First Name Middle Initial Sex Date of Birth Alberta Personal Health Number M
More informationProgram Highlights. A multidisciplinary AAN working group identified areas for improvement in the diagnosis and management of patients with MS
CasePerspectives: Illuminating Dark Pathways in Complex MS Cases Program Highlights Stephen Krieger, MD Associate Professor of Neurology Corinne Goldsmith Dickinson Center for MS Director, Neurology Residency
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Tysabri) Reference Number: HIM.PA.SP17 Effective Date: 05.01.17 Last Review Date: 05.18 Line of Business: Health Insurance Marketplace Coding Implications Revision Log See Important Reminder
More informationMultiple Sclerosis: More Than Your ABC s. Technician Objectives. Pharmacist Objectives. Pretest Question. Pretest Question 9/22/16
Disclosure and Conflict of Interest Multiple Sclerosis: More Than Your ABC s Janene L. Marshall, PharmD, BCPS Clinical Associate Professor Internal Medicine Clinical Pharmacist Chicago State University
More informationUpdate in Multiple Sclerosis
Update in Multiple Sclerosis Kyle Smoot, MD Providence MS Center Portland, OR 1 Disclosures Research funds from Biogen. Consulting fees from Acorda, Biogen, EMDSerono, Genzyme, Novartis, and Teva. 2 Outline
More informationClinical Policy: Natalizumab (Tysabri) Reference Number: ERX.SPA.162 Effective Date:
Clinical Policy: (Tysabri) Reference Number: ERX.SPA.162 Effective Date: 10.01.16 Last Review Date: 11.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Tysabri) Reference Number: HNMC.CP.PHAR.259 Effective Date: 07.01.16 Last Review Date: 05.18 Line of Business: Medicaid Medi-Cal Coding Implications Revision Log See Important Reminder
More information2. Has this plan authorized this medication in the past for this member (i.e., previous authorization is on file under this plan)?
Pharmacy Prior Authorization AETA BETTER HEALTH EW JERSE (MEDICAID) Multiple Sclerosis (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information,
More informationClinical Policy: Natalizumab (Tysabri) Reference Number: ERX.SPA.162 Effective Date:
Clinical Policy: (Tysabri) Reference Number: ERX.SPA.162 Effective Date: 10.01.16 Last Review Date: 11.17 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationDo you or did you have any family members who have been diagnosed with MS? Yes No I Don t Know. Yes identical Yes not identical No
The following survey will ask you questions about your family history of MS, your MS diagnosis and history, your symptoms, and your treatments. You may find it easier to fully answer these questions if
More informationClinical Policy: Natalizumab (Tysabri) Reference Number: CP.PHAR.259 Effective Date: Last Review Date: Line of Business: Medicaid
Clinical Policy: (Tysabri) Reference Number: CP.PHAR.259 Effective Date: 07.01.16 Last Review Date: 05.18 Line of Business: Medicaid Coding Implications Revision Log See Important Reminder at the end of
More informationCurrent Enrolling Clinical Trials
ASSESS RRMS patients with active disease who are still able to walk. Mariko Kita MD Description of Study/Trial: A 12-month, randomized, rater- and dose-blinded study to compare the efficacy and safety
More informationHot Topics Multiple Sclerosis. Natalie Parks, MD, FRCPC Assistant Professor, Dalhousie University June 27, 2018
Hot Topics Multiple Sclerosis Natalie Parks, MD, FRCPC Assistant Professor, Dalhousie University June 27, 2018 Disclosures Natalie Parks has received compensation from Biogen, EMD Serono, Roche, and Sanofi
More informationA Glimpse at Immunomodulators in MS
A Glimpse at Immunomodulators in MS An Interview with Mark S. Freedman, HBSc, MSc, MD, CSPQ, FAAN, FRCPC Multiple Sclerosis Research Unit, University of Ottowa, Ottowa Canada Ottawa Hospital Research Institute,
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Tysabri) Reference Number: HIM.PA.SP17 Effective Date: 05.01.17 Last Review Date: 11.18 Line of Business: Health Insurance Marketplace Coding Implications Revision Log See Important Reminder
More informationCarolyn Taylor, M.D. Swedish Neuroscience Center
Carolyn Taylor, M.D. Swedish Neuroscience Center When should disease modifying therapy be discontinued in MS? Should we be using aggressive treatments earlier in the MS disease course and reserving the
More informationOcrevus. (ocrelizumab) New Product Slideshow
Ocrevus (ocrelizumab) New Product Slideshow Introduction Brand name: Ocrevus Generic name: Ocrelizumab Pharmacological class: CD20-directed cytolytic monoclonal antibody Strength and Formulation: 30mg/mL;
More informationProgress in MS: Current and Emerging Therapies. Presented by: Dr. Kathryn Giles, MD MSc FRCPC Cambridge, Ontario, Canada
Progress in MS: Current and Emerging Therapies Presented by: Dr. Kathryn Giles, MD MSc FRCPC Cambridge, Ontario, Canada Today s Discussion Natural History and Classification of MS Treating MS Management
More informationClinical Policy: Natalizumab (Tysabri) Reference Number: CP.PHAR.259 Effective Date: Last Review Date: Line of Business: Medicaid
Clinical Policy: (Tysabri) Reference Number: CP.PHAR.259 Effective Date: 07.01.16 Last Review Date: 11.18 Line of Business: Medicaid Coding Implications Revision Log See Important Reminder at the end of
More informationTREATING MULTIPLE SCLEROSIS The Current Disease Modifying Therapies Beverly Gilder, M.D. Blue Sky Neurology MS Center
TREATING MULTIPLE SCLEROSIS 2018 The Current Disease Modifying Therapies Beverly Gilder, M.D. Blue Sky Neurology MS Center Welcome Thank you for joining us! Today you will learn about MS treatment choices
More informationGILENYA (fingolimod) oral capsule
GILENYA (fingolimod) oral capsule Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy Coverage
More informationFor all requests for Multiple Sclerosis Medications all of the following criteria must be met:
Request for Prior Authorization for Multiple Sclerosis Medications Website Form www.highmarkhealthoptions.com Submit request via: Fax - 1-855-476-4158 All requests for Multiple Sclerosis Medications require
More informationAnticipated Launches Q Q1 2019
Anticipated Launches Q4 2018-Q1 2019 Disease Prevalence Amyloidosis Tegsedi (inotersen) subcutaneous (SC) injection Akcea s/ionis Pharmaceuticals hereditary transthyretin amyloidosis (hattr) with polyneuropathy,
More informationKristen Helms, PharmD Clinical Associate Professor Department of Pharmacy Practice and Office of Teaching, Learning and Assessment Auburn University
Kristen Helms, PharmD Clinical Associate Professor Department of Pharmacy Practice and Office of Teaching, Learning and Assessment Auburn University Harrison School of Pharmacy Auburn, Alabama Presenter:
More informationProgressive Multiple Sclerosis
Progressive Multiple Sclerosis Definitions, Clinical Course and Emerging Therapies M. Mateo Paz Soldán, MD, PhD Neurology Service, VA Salt Lake City HCS Assistant Professor of Neurology, University of
More informationMultiple Sclerosis , The Patient Education Institute, Inc. nr Last reviewed: 04/17/2017 1
Multiple Sclerosis Introduction Multiple sclerosis, or MS, is a disease of the brain and spinal cord. Most patients with multiple sclerosis are able to lead a very functional life. However, MS causes a
More informationNEUROLOGY UPDATE IV: MULTIPLE SCLEROSIS
NEUROLOGY UPDATE IV: MULTIPLE SCLEROSIS Learning Objectives Daniel Harrison, MD University of Maryland School of Medicine Baltimore, MD Upon completion of this module, participants should be familiar with:
More informationOCREVUS (ocrelizumab) Injection, for Intravenous Use
OCREVUS (ocrelizumab) Injection, for Intravenous Use Heidi Crayton, MD Medical Director Multiple Sclerosis Center of Greater Washington Vienna, VA OCR/071916/0181(1) Disclaimer This program is presented
More informationPharmacotherapy Update Multiple Sclerosis
Pharmacotherapy Update Multiple Sclerosis Yolande Hanssens SIG Leader Medicine Information Hamad Medical Corporation Pharmacy Department - Clinical Service Unit Doha - Qatar Heidelberg/October 2017 Pharmacotherapy
More informationDisease-modifying therapies
Updated May 2018. Please check nationalmssociety.org/dmt for the most current version of this publication. For some people, a diagnosis of multiple sclerosis (MS) is a relief, giving a name and a reason
More informationAscertaining the Role of the Primary Care Clinician in the Recognition and Management of Patients With Multiple Sclerosis in the Modern Era
Ascertaining the Role of the Primary Care Clinician in the Recognition and Management of Patients With Multiple Sclerosis in the Modern Era Edward J. Fox, MD, PhD MS Clinic of Central Texas Central Texas
More informationWelcome to today s webinar: Learn about MS
Welcome to today s webinar: Learn about MS Your Presenter is Dr Todd Hardy Your Facilitator is Belinda Saunders Housekeeping Thanks for joining us for this webinar welcome! You will be able to: hear the
More informationMellen Center Approach to Ocrelizumab (Ocrevus)
Mellen Center Approach to Ocrelizumab (Ocrevus) Q: What is mechanism of action of ocrelizumab? A; Ocrelizumab is a novel humanized monoclonal anti-cd20 antibody constructed with recombinant DNA techniques
More informationDemyelinating Diseases: Multiple Sclerosis January 10, 2018 Dr. Ostrow
Demyelinating Diseases: Multiple Sclerosis January 10, 2018 Dr. Ostrow Reading: Robbins & Cotran, 9 th edition, pp 1283-1286 Robbins Basic Pathology, 9 th edition, 832-835 Overview: Grossly, myelin is
More informationClinician s view of Benefit-Risk
Clinician s view of Benefit-Risk Gordon Francis, MD Novartis, Clinical Development Clinician s View of Benefit-Risk: a need for reliable metrics A tale of 3 drugs Natalizumab MS Crohn s Disease Fingolimod
More information2013 MS Phenotype Descriptions: Relapsing MS 1
2013 MS Phenotype Descriptions: Relapsing MS 1 Disease-Modifying Therapies? which can be found in its entirety at. Clinically isolated syndrome (CIS) Not Active a Active a,b Relapsing-remitting disease
More informationObjectives. There Aren t Enough Hours in the Day
There Aren t Enough Hours in the Day Medication monitoring and communication of results Objectives Review the types of testing being ordered on patients receiving therapies other than platforms Discuss
More informationChoices. Disease modifying treatments. Read me
Choices Disease modifying treatments Read me Disease modifying treatments Disease modifying therapies (DMTs) are medications which modify the course of multiple sclerosis (MS) and are designed to reduce
More informationMultiple Sclerosis: The Safety Efficacy Balance and Preventing Neurodegeneration
Multiple Sclerosis: The Safety Efficacy Balance and Preventing Neurodegeneration Introduction The treatment landscape for multiple sclerosis (MS) has seen extensive growth over the last several decades.
More informationSubject: Natalizumab (Tysabri ) IV
09-J0000-73 Original Effective Date: 03/15/08 Reviewed: 11/14/18 Revised: 12/15/18 Subject: Natalizumab (Tysabri ) IV THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION, EXPLANATION
More informationThe invisible facets of MS and everyday challenges clinician s perspective. Mar Tintore
The invisible facets of MS and everyday challenges clinician s perspective Mar Tintore Centre d Esclerosi Múltiple de Catalunya (Cemcat). Department of Neurology/Neuroimmunology Hospital Universitari Vall
More informationHorizon Scanning Centre July Ocrelizumab for relapsing-remitting multiple sclerosis SUMMARY NIHR HSC ID: 3711
Horizon Scanning Centre July 2014 Ocrelizumab for relapsing-remitting multiple sclerosis SUMMARY NIHR HSC ID: 3711 This briefing is based on information available at the time of research and a limited
More informationDISEASE-MODIFYING THERAPIES FOR MS
DISEASE-MODIFYING THERAPIES FOR MS Updated December 2018. Please check nationalmssociety.org/dmt for the most current version of this publication. A multiple sclerosis (MS) diagnosis can bring a sense
More informationCircle Yes or No Y N. [If no, skip to question 8.] 2. Has the patient been compliant with therapy as verified by the prescriber?
06/01/2016 Prior Authorization AETA BETTER HEALTH OF MICHIGA (MEDICAID) Tecfidera (MI88) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information,
More informationLocal Natalizumab Treatment Protocol
Local Natalizumab Treatment Protocol 1. New medicine name: Natalizumab 300mg concentrate for solution for infusion (Natalizumab ) 2. Licensed indication(s): Natalizumab is indicated for single disease
More informationUpdates to the Alberta Human Services Drug Benefit Supplement
Updates to the Alberta Human Services Drug Benefit Supplement Effective December 9, 2013 Inquiries should be directed to: Pharmacy Services Alberta Blue Cross 10009 108 Street NW Edmonton AB T5J 3C5 Telephone
More informationJournal homepage:
Multiple Sclerosis: Promising New Treatment - A Clinical Review Abdulrahman M Alshahrani Consultant Neurologist, Riyadh, Saudi Arabia ABSTRACT Objective: In this update on multiple sclerosis, the main
More informationPharmacy Prior Authorization
Pharmacy Prior Authorization AETA BETTER HEALTH VIRGIIA Multiple Sclerosis Agents (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information,
More informationDISCLAIMER FDA INDICATIONS INITIAL COVERAGE CRITERIA POSITION STATEMENT. Subject: Aubagio (teriflunomide) Original Effective Date: 10/30/2013
Subject: Aubagio (teriflunomide) Original Effective Date: 10/30/2013 Policy Number: MCP-146 Revision Date(s): Review Date(s): 12/16/15; 6/15/2016; 3/21/2017 DISCLAIMER This Molina Clinical Policy (MCP)
More informationMellen Center Approaches: Natalizumab
Cleveland Clinic Mellen Center for Multiple Sclerosis Treatment and Research 216.444.8600 Mellen Center Approaches: Natalizumab Who should be considered for Natalizumab therapy? In the phase II and phase
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 20 July 2011
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 20 July 2011 GILENYA 0.5 mg, hard capsules, perforated unit dose blister packs B/7 (CIP code: 417 785-3) GILENYA 0.5
More informationMULTIPLE SCLEROSIS. Immunologic Features Most immunopathologic studies have been completed in adults with MS. In a study comparing 10 children with
Pediatric-Onset Multiple Sclerosis Information from clinical trials in children with MS is furthering understanding and improving treatment options for this rare presentation. By Duriel I. Hardy, MD and
More informationActivity presentations are considered intellectual property.
Activity presentations are considered intellectual property. Activity presentations are considered intellectual property and are for viewing purposes only. No content should be copied or reproduced in
More informationUpdates to the Alberta Drug Benefit List. Effective August 1, 2018
Updates to the Alberta Drug Benefit List Effective August 1, 2018 Inquiries should be directed to: Pharmacy Services Alberta Blue Cross 10009 108 Street NW Edmonton AB T5J 3C5 Telephone Number: (780) 498-8370
More informationThe Effects of Daclizumab High Yield Process (DAC HYP) on Patient Centered Functional Outcomes: Results From the DECIDE Study
2015 Annual Meeting of the Consortium of Multiple Sclerosis Centers May 27 30, 2015 Indianapolis, IN The Effects of Daclizumab High Yield Process () on Patient Centered Functional Outcomes: Results From
More informationMS Academia: Multiple sclerosis advanced course
6 October 2015 - Barcelona, Spain MS Academia: Multiple sclerosis advanced course IMPROVING THE PATIENT S LIFE THROUGH MEDICAL EDUCATION www.excemed.org Mark S. Freedman University of Ottawa and the Ottawa
More informationnatalizumab (Tysabri )
natalizumab (Tysabri ) Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ),
More informationPrior Authorization. Drug Name (select from list of drugs shown) Gilenya (fingolomid) Quantity Frequency Strength. Physician Name:
06/01/2016 Prior Authorization Aetna Better Health Michigan Gilenya This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign and date. Fax signed
More informationHorizon Scanning Centre July Daclizumab High Yield Process for relapsing forms of multiple sclerosis first or second line
Horizon Scanning Centre July 2014 Daclizumab High Yield Process for relapsing forms of multiple sclerosis first or second line SUMMARY NIHR HSC ID: 2635 This briefing is based on information available
More informationMDWISE PRIOR AUTHORIZATION CRITERIA TYSABRI (natalizumab): 300mg/15mL single use vial
MDWISE PRIOR AUTHORIZATION CRITERIA TYSABRI (natalizumab): 300mg/15mL single use vial Formulary Status: Non-Formulary requiring prior authorization PA CRITERIA FOR INITIAL AUTHORIZATION FOR USE IN MULTIPLE
More informationVesicular Demyelination in MS A Pattern of Humoral Immune Pathology Multiple Sclerosis: B-Cells Take Center Stage
Vesicular Demyelination in MS A Pattern of Humoral Immune Pathology Multiple Sclerosis: B-Cells Take Center Stage Stephen L. Hauser, M.D. CD2 B cells in an MS lesion CD2 B cells in an MS lesion 1 CD138
More informationNeuroimaging and Other Biomarkers. MRI for Diagnosis, Prognosis and Treatment Decisions in MS
Neuroimaging and Other Biomarkers MRI for Diagnosis, Prognosis and Treatment Decisions in MS Eric Klawiter, MD MSc Massachusetts General Hospital May 30, 2014 Disclosures and Funding Disclosures: Consulting
More informationInvestor Update. Downloads. Services PDF. Basel, 17 July 2017
Investor Update Basel, 17 July 2017 Roche s OCREVUS (ocrelizumab) approved for relapsing and primary progressive multiple sclerosis in Australia Second approval after the US for OCREVUS as the first and
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
H.P. Acthar Gel (repository corticotropin) Page 1 of 7 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: H.P. Acthar Gel (repository corticotropin) Prime Therapeutics
More informationClinical Case Study Discussion of Demyelinating Diseases. Mirela Cerghet, MD, PhD Henry Ford Hospital August 6, 2011
Clinical Case Study Discussion of Demyelinating Diseases Mirela Cerghet, MD, PhD Henry Ford Hospital August 6, 2011 No financial disclosures Will discuss use of non-fda approved medication CONTENT Case
More informationRegulatory Status FDA-approved indication: Tecfidera is indicated for the treatment of patients with relapsing forms of multiple sclerosis (1).
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.60.01 Subject: Tecfidera Page: 1 of 5 Last Review Date: December 2, 2016 Tecfidera Description Tecfidera
More informationMULTIPLE SCLEROSIS Management and Therapy
MULTIPLE SCLEROSIS Management and Therapy 115 th Oklahoma Osteopathic Association Annual Convention April 30 th, 2015 Anthony J. Vaughn, M.D. ANTHONY J. VAUGHN, M.D. Assistant Professor Director, Clinical
More informationTreatment Algorithm for Multiple Sclerosis Disease-modifying Therapies
Treatment Algorithm for Multiple Sclerosis Disease-modifying Therapies NHS England Reference: 170079ALG Date Published: 4 September 2018 Gateway reference: 07603 Treatment Algorithm for Multiple Sclerosis
More informationMultiple sclerosis. Tünde Csépány MD. PhD. 08. November 2017.
Multiple sclerosis Tünde Csépány MD. PhD. 08. November 2017. Multiple Sclerosis Approximately 350 000 people in the United States are affected by MS Prevalence strongly dependent on latitude (25-224/100
More informationPositive Phase III results for Roche s investigational medicine OCREVUS (ocrelizumab) published in New England Journal of Medicine
Media Release Basel 21 December 2016 Positive Phase III results for Roche s investigational medicine OCREVUS (ocrelizumab) published in New England Journal of Medicine OCREVUS is the first and only investigational
More informationHealth-Related Quality of Life in Patients with Multiple Sclerosis: Impact of Disease-Modifying Drugs
CNS Drugs (2017) 31:585 602 DOI 10.1007/s40263-017-0444-x REVIEW ARTICLE Health-Related Quality of Life in Patients with Multiple Sclerosis: Impact of Disease-Modifying Drugs Peter Joseph Jongen 1,2 Published
More informationProgress in the field
Progress in the field Eva Havrdová Charles University in Prague 1st Medical Faculty and General University Hospital Disclosures Dr. Havrdová has received consulting fees from Actelion, Biogen Idec, Merck,
More informationMultiple Sclerosis: Emerging Therapies
Multiple Sclerosis: Emerging Therapies Bruce Cree, MD, PhD, MCR Conflicts of Interest EMD Serono: Grant support ovartis: Adviser, Clinical Trial Participant What are the Future Considerations for MS Therapies?
More informationMedia Release. Basel, 10 November 2017
Media Release Basel, 10 November 2017 Roche s OCREVUS (ocrelizumab) gains positive CHMP opinion for relapsing forms of multiple sclerosis and primary progressive multiple sclerosis If approved, OCREVUS
More informationMEDICATION FOR MULTIPLE SCLEROSIS
MEDICATION FOR MULTIPLE SCLEROSIS Ocrelizumab effect and safety Alsafa Oudah Examensarbete I farmaci, 15 hp Apotekarprogrammet, 300 hp Report approved: Spring term 2018 Supervisor: Miles Trupp, Examiner:
More informationBeyond Efficacy and Safety: Where We Go From Here in the Management of Multiple Sclerosis
Beyond Efficacy and Safety: Where We Go From Here in the Management of Multiple Sclerosis Introduction When selecting a disease-modifying therapy (DMT) for patients with multiple sclerosis (MS), clinicians
More informationMS Academia: Multiple sclerosis advanced course
13 September 2016 - London, UK MS Academia: Multiple sclerosis advanced course IMPROVING THE PATIENT S LIFE THROUGH MEDICAL EDUCATION www.excemed.org Robert J. Fox Assessment of treatment response IMPROVING
More informationPharmacy Management Drug Policy
SUBJECT: Multiple Sclerosis, Crohn s Disease POLICY NUMBER: PHARMACY-53 EFFECTIVE DATE: 4/08 LAST REVIEW DATE: 12/18/2018 If the member s subscriber contract excludes coverage for a specific service or
More informationPharmacist Objectives. Pathophysiology. Pathophysiology 9/4/2014. At the conclusion of this program, the pharmacist will be able to:
Speaker Disclosure Amanda Stahnke, PharmD, BCACP declares no conflicts of interest, real or apparent, and no financial interests in any company, product, or service mentioned in this program, including
More information